Background: A reverse association between cholesterol level and cardiovascular disease mortality is observed in hemodialysis (HD) patients; this paradoxical relationship may be explained by the coexistence of inflammation. Interleukin-6 (IL-6) is a central regulator of inflammation; its action is augmented by the soluble IL-6 receptor (sIL-6R) and inhibited by the soluble gp130 (sgp130). In order to investigate the potential association of inflammation with cholesterol levels in the HD population, release of soluble IL-6 components by peripheral blood mononuclear cells (PBMCs) was measured in two groups of HD patients with distinctly different lipid profile and in a control group. Methods: Twenty-two HD patients with low serum cholesterol (range 85–171 mg/dl), 23 HD patients with high cholesterol (189–342 mg/dl) and 21 normolipidemic non-renal failure subjects were enrolled in the study. IL-6, sIL-6R and sgp130 were measured by ELISA in the serum and in the supernatant collected from cell cultures of activated or resting PBMCs isolated from all three groups. Results: Serum IL-6 and sgp130 level was higher while sIL-6R was lower in both groups of HD patients compared to the control group. The ex-vivo release of the IL-6 and sgp130 by unstimulated PBMCs did not differ significantly between the three groups but that of the sIL-6R was higher in non-renal failure than in hypercholesterolemic HD subjects. Production of sIL-6R by stimulated PBMCs was higher in low-cholesterol HD patients (p < 0.001) and the same was valid for the sgp130 release (p = 0.034). Release of IL-6 by activated PBMCs was higher in the low-cholesterol compared to the high-cholesterol HD patients group (p = 0.011 for post hoc test). Major serum lipid fractions were inversely correlated to IL-6 and sIL-6R production from stimulated PBMCs in HD but not in non-renal failure subjects. Finally, release of the sgp130 by PBMCs was significantly reduced in 13 hypertriglyceridemic – and hypercholesterolemic – HD patients. Conclusion: Production of soluble components of a crucial pro-inflammatory and potentially atherogenic cytokine, namely the IL-6, by stimulated PBMCs appears to be inversely correlated with the serum cholesterol levels in HD patients.

Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD: Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003;63:793–808.
Liu Y, Coresh J, Eustace JA, et al: Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 2004;291:451–459.
Hansson KG: Inflammation, atherosclerosis, and coronary disease. N Engl J Med 2005;352:1685–1695.
Pecoits-Filho R, Lindholm B, Axelsson J, Stenvinkel P: Update on interleukin-6 and its role in chronic renal failure. Nephrol Dial Transplant 2003;18:1042–1045.
Jones SA, Horiuchi S, Topley N, et al: The soluble interleukin-6 receptor: Mechanisms of production and implications in disease. FASEB J 2001;15:43–58.
Jostock T, Mullberg J, Ozbek S, et al: Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem 2001;268:160–167.
Memoli B, Postiglione L, Cianciaruso B, et al: Role of different dialysis membranes in the release of interleukin-6 soluble receptor in uremic patients. Kidney Int 2000;58:417–424.
Lessner SM, Prado HL, Waller EK, Galis ZS: Atherosclerotic lesions grow through recruitment and proliferation of circulating monocytes in a murine model. Am J Pathol 2002;160:2145–2155.
Matthews V, Schuster B, Schutze S, et al: Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem 2003;278:38829–38839.
von Tresckow B, Kallen KJ, von Strandmann EP, et al: Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J Immunol 2004;172:4324–4331.
Cherukuri A, Dykstra M, Pierce SK: Floating the raft hypothesis: Lipid rafts play a role in immune cell activation. Immunity 2001;14:657–600.
Kim J, Adam RM, Solomon KR, Freeman MR: Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology 2004;145:613–619.
Reznikov LL, Waksman J, Azam T, et al: Effect of advanced glycation end products on endotoxin-induced TNF-alpha, IL-1beta and IL-8 in human peripheral blood mononuclear cells. Clin Nephrol 2004;61:324–336.
Ambrosch A, Muller R, Freytag C, et al: Small-sized low-density lipoproteins of subclass B from patients with end-stage renal disease effectively augment tumor necrosis factor-alpha-induced adhesive properties in human endothelial cells. Am J Kidney Dis 2002;39:972–984.
Liuba P, Persson J, Luoma J, Yla-Herttuala S, Pesonen E: Acute infections in children are accompanied by oxidative modification of LDL and decrease of HDL cholesterol, and are followed by thickening of carotid intima media. Eur Heart J 2004;24:515–521.
Liberopoulos E, Siamopoulos K, Elisaf M: Apolipoprotein E and renal disease. Am J Kidney Dis 2004;43:223–233.
Axelsson J, Rashid Qureshi A, Suliman ME, et al: Truncal fat mass as a contributor to inflammation in end-stage renal disease. Am J Clin Nutr 2004;80:1222–1229.
Stenvinkel P, Heimburger O, Lindholm B: Wasting, but not malnutrition, predicts cardiovascular mortality in end-stage renal disease. Nephrol Dial Transplant 2004;19:2181–2183.
Wanner C, Quaschning T: Dyslipidemia and renal disease: Pathogenesis and clinical consequences. Curr Opin Nephrol Hypertens 2001;10:195–201.
Quaschning T, Schoming M, Keller M, et al: Non-insulin-dependent diabetes mellitus and hypertriglyceridemia impair lipoprotein metabolism in chronic hemodialysis patients. J Am Soc Nephrol 1999;10:322–341.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.